At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 180 enrolled
Drug / intervention
Dexamethasone 0.1% ophthalmic suspension +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model
In Brief
A Phase 4 clinical trial evaluating Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution, and 1 other intervention for Allergic Conjunctivitis. Completed, enrolled 180 participants across 1 site.
Detailed Summary
The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedMay 2010
Primary CompletionSep 2010
TodayJul 2026
First PostedMay 7, 2010
Enrollment StartMar 1, 2010
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.2 years ago
Interventions
Dexamethasone 0.1% ophthalmic suspensiondrug
Maxidex
Olopatadine hydrochloride 0.1% ophthalmic solutiondrug
Patanol
Inactive ingredients, used as placeboother
Tears Naturale II